Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma

Cancer

Volumn 117, Issue 9, 2011, Pages 1901-1910

  Dietrich, Sascha ^a   Tielesch, Blanca ^a   Rieger, Michael ^a   Nickelsen, Maike ^b   Pott, Christiane ^c   Witzens Harig, Mathias ^a   Kneba, Michael ^c   Schmitz, Norbert ^b   Ho, Antony D ^a   Dreger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Asklepios Clinic   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

allogeneic stem cell transplantation; autologous stem cell transplantation; mantle cell lymphoma; relapse; rituximab

Indexed keywords

BORTEZOMIB; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; KI 67 ANTIGEN; MELPHALAN; MITOXANTRONE; OXALIPLATIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CD34 SELECTION; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MENINX DISORDER; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; OPHTHALMOPLEGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SALVAGE THERAPY; SOLID TUMOR; VISUAL FIELD DEFECT; WHOLE BODY RADIATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79955401258     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25756     Document Type: Article

References (37)

1. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol. 1995; 6: 257-262.
2. Pittaluga S, Wlodarska I, Stul MS, et al. Mantle cell lymphom a: a clinicopathological study of 55 cases. Histopathology. 1995; 26: 17-24.
3. Vandenberghe E., Mantle cell lymphoma. Blood Rev. 1994; 8: 79-87. (Pubitemid 24216115)
4. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009; 27: 511-518.
5. Dreger P, Martin S, Kuse R, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of 2 prospective studies with 46 patients. Hematol J. 2000; 1: 87-94.
6. Kroger N, Hoffknecht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant. 1998; 21: 55-57. (Pubitemid 28043437)
7. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998; 16: 3803-3809. (Pubitemid 29001533)
8. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998; 16: 13-18. (Pubitemid 28041573)
9. Haas R, Brittinger G, Meusers P, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia. 1996; 10: 1975-1979. (Pubitemid 27019647)
10. Stewart DA, Vose JM, Weisenburger DD, et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol. 1995; 6: 263-266.
11. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO., Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol. 2005; 16: 618-624. (Pubitemid 40613329)
12. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008; 112: 2687-2693.
13. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005; 105: 2677-2684. (Pubitemid 40450320)
14. Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica. 2007; 92: 42-49. (Pubitemid 46237555)
15. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003; 102: 749-755. (Pubitemid 36842002)
16. Dreger P, Viehmann K, von Neuhoff N, et al. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant. 1999; 24: 153-161. (Pubitemid 29351829)
17. Kornacker M, Stumm J, Pott C, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009; 20: 722-728.
18. Pott C, Tiemann M, Linke B, et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia. 1998; 12: 1630-1637. (Pubitemid 28470450)
19. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17: 2257-2317. (Pubitemid 38072572)
20. Altman DG, De Stavola BL, Love SB, Stepniewska KA., Review of survival analyses published in cancer journals. Br J Cancer. 1995; 72: 511-518.
21. Hoster E, Metzner B, Forstpointner R, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 880.
22. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009; 113: 4144-4152.
23. Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O., Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica. 2004; 89: 1275-1276. (Pubitemid 39390461)
24. Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant. 1998; 22: 645-650. (Pubitemid 28486362)
25. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005; 131: 29-38. (Pubitemid 43899705)
26. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008; 111: 2385-2387. (Pubitemid 351451450)
27. Hartmann E, Fernandez V, Moreno V, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol. 2008; 26: 4966-4972.
28. Klapper W, Hoster E, Determann O, et al. for the European MCL Network. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network [published online ahead of print June 16, 2009]. J Hematop. 2009.
29. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003; 3: 185-197. (Pubitemid 37443390)
30. Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2006; 103: 2352-2357. (Pubitemid 43271673)
31. Sander S, Bullinger L, Leupolt E, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Haematologica. 2008; 93: 680-687. (Pubitemid 351669307)
32. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111: 558-565.
33. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010; 115: 1530-1533.
34. Pott, C, Schrader, C, Gesk, S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006; 107: 2271-2278. (Pubitemid 43345544)
35. Maris, MB, Sandmaier, BM, Storer, BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004; 104: 3535-3542. (Pubitemid 39564424)
36. Khouri, IF, Lee, MS, Saliba, RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003; 21: 4407-4412. (Pubitemid 46621818)
37. Martin, P, Chadburn, A, Christos, P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009; 27: 1209-1213.